Abstract Number: 938 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity
Background/Purpose: Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the…Abstract Number: 2117 • 2019 ACR/ARP Annual Meeting
Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis
Background/Purpose: A previous meta-analysis1 showed that tapering of bDMARDs does not increase the risk of relapse in rheumatoid arthritis (RA) patients with remission or low…Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…Abstract Number: 63 • 2018 ACR/ARHP Annual Meeting
TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis
Background/Purpose: Interstitial lung disease (ILD) is a significant contributor to rheumatoid arthritis (RA) mortality, yet its pathogenesis remains enigmatic. One theory posits that initial inflammatory…Abstract Number: 2429 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of Children Born to Mothers with Chronic Arthritis and Exposed to TNF-Inhibitors during Pregnancy: A Case-Control Study
Background/Purpose: Treatment with tumor necrosis factors inhibitors (TNFi) during pregnancy may be required to control maternal disease which can be a threat for maternal-fetal well-being.…Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…Abstract Number: 2557 • 2018 ACR/ARHP Annual Meeting
Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis
Background/Purpose: In PSUMMIT 1&2, Phase 3 trials of ustekinumab (UST) in adults w/ active psoriatic arthritis (PsA), 30.1% & 22.4% of patients (pts) had peripheral…Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting
The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study
Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…Abstract Number: 2558 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
Background/Purpose: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained…Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…Abstract Number: 2580 • 2018 ACR/ARHP Annual Meeting
Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison
Background/Purpose: The purpose of this study was to compare treatment patterns in the 2 years following the initiation of TNF inhibitor (TNFi) in AS patients.Methods:…Abstract Number: 584 • 2018 ACR/ARHP Annual Meeting
Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Background/Purpose: TNF inhibitors (TNFi) are widely used for the treatment of rheumatoid arthritis (RA). This study aims to analyse the profile of peripheral blood mononuclear…Abstract Number: 2599 • 2018 ACR/ARHP Annual Meeting
The Agreement between TNFi Treatment Responses and Fatigue Responses Is Weak to Moderate Suggesting Heterogeneity between Experienced Fatigue and Joint Inflammation: A Danish Population-Based Cohort Study
Background/Purpose: Despite better control of inflammation, e.g. with biological treatments, some patients with psoriatic arthritic (PsA) continue to cite fatigue as one of the most…Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 29
- Next Page »